Corvus Pharmaceuticals, Inc.
CRVS
$13.95
-$0.13-0.92%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.55% | -11.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.56% | 3.04% | |||
| Operating Income | -15.56% | -3.04% | |||
| Income Before Tax | -21.31% | -26.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.31% | -26.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.31% | -26.99% | |||
| EBIT | -15.56% | -3.04% | |||
| EBITDA | -15.62% | -3.06% | |||
| EPS Basic | -21.04% | -19.26% | |||
| Normalized Basic EPS | -21.15% | -19.13% | |||
| EPS Diluted | -21.04% | -19.26% | |||
| Normalized Diluted EPS | -21.15% | -19.13% | |||
| Average Basic Shares Outstanding | 0.20% | 6.51% | |||
| Average Diluted Shares Outstanding | 0.20% | 6.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||